蔡洪庆,万经海.成人胶质母细胞瘤免疫治疗的新进展[J].,2017,4(10):9-11.
成人胶质母细胞瘤免疫治疗的新进展
Advances in immunotherapy for adult glioblastoma multiforme.
投稿时间:2017-05-08  最后修改时间:2017-05-15
DOI:
中文关键词:  胶质母细胞瘤;免疫治疗
英文关键词:glioblastoma, immunotherapy
基金项目:
作者单位E-mail
蔡洪庆 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院神经外科 phonecy@126.com 
万经海 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院神经外科 wanjinghai@sina.com 
摘要点击次数: 304
全文下载次数: 2900
中文摘要:
      胶质母细胞瘤是成人原发恶性神经系统肿瘤中最常见的病理类型,尽管术后积极的进行辅助治疗,其预后仍较差。目前已有较多的免疫治疗方案在肿瘤中使用,有些治疗方式具有较好的安全性和有效性。成人胶质母细胞瘤中免疫治疗的研究主要集中在树突状细胞免疫治疗(DCs)、多肽疫苗治疗、过继免疫治疗(ACTs)及免疫节点抑制剂治疗等四种治疗方式上,部分在临床前实验甚至早期临床试验中都表现出较好的抗肿瘤效果,但仍需要更高级别的临床试验证据支持。
英文摘要:
      Glioblastoma is the most common pathological type in adult primary tumors of the central nervous system. Although treated with surgery and postoperative adjuvant therapy, the prognosis is still poor. At present, there are increasing number of immunotherapy studys in the tumor. Some of them have better clinical safety and effectiveness. The immunotherapy studys in adult glioblastoma mainly focus on four treatment options: dendritic cell immunotherapy (DCs), peptide vaccine therapy, adoptive immunotherapy (ACTs) and checkpoint inhibitors. Preclinical experiments and early clinical trials have shown better anti-tumor effect. But there is an urgent need for higher level clinical trial evidence to support effectiveness of immunotherapy.
查看全文  查看/发表评论  下载PDF阅读器
关闭